4D Molecular Therapeutics (FDMT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Platform and pipeline overview

• Focused on next-generation gene therapy, with 4D-150 as the lead program targeting wet AMD and DME, both in advanced clinical trials.

• Phase III trials 4FRONT-1 and 4FRONT-2 for wet AMD are underway, with DME trial initiation planned for later this year.

• Additional programs include cystic fibrosis (4D-710), with an update expected by year-end.

Clinical development and catalysts

• Key data readouts: 4FRONT-1 phase III in H1 next year, 4FRONT-2 in H2 next year.

• Two-year duration updates for PRISM (wet AMD) and DME phase II expected this year.

• Cystic fibrosis program update with 9-12 months of data on 12 patients expected in H2 this year.

Regulatory and trial design

• Productive and standard interactions with FDA; phase III designs mirror successful precedents in the field.

• Global trial enrollment for 4FRONT-2 is robust, with likely over-enrollment, reflecting strong physician and patient enthusiasm.

• Non-inferiority on vision at week 52 is the primary endpoint, with safety and significant reduction in treatment burden as key differentiators.